Similar articles

• When and how to use tipranavir and darunavir.

  Hoffman CJ, Gallant JE. Hoffman CJ, et al. AIDS Read. 2007 Apr;17(4):194-8, 201. AIDS Read. 2007. PMID: 17479503 Review. No abstract available.
• Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.

  Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC. Hsieh SM, et al. Int J STD AIDS. 2011 Nov;22(11):617-20. doi: 10.1258/ijsa.2009.009007. Int J STD AIDS. 2011. PMID: 22096044
• A lame duck, a dark horse, and a goat.

  Huff B. Huff B. GMHC Treat Issues. 2005 May-Jun;19(5-6):4-5. GMHC Treat Issues. 2005. PMID: 16193576 No abstract available.
• FDA notifications. Accelerated approval of tipranavir.

  [No authors listed] [No authors listed] AIDS Alert. 2005 Nov;20(11):131. AIDS Alert. 2005. PMID: 16363051 No abstract available.
• Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).

  Arribas JR. Arribas JR. Curr Opin HIV AIDS. 2009 Nov;4(6):507-12. doi: 10.1097/COH.0b013e328331b911. Curr Opin HIV AIDS. 2009. PMID: 20048718 Review.